Cofactor Genomics Announces New U.S. Patent Granted for Predictive Immune Modeling Technology

Patent Represents Major Step Towards Bridging the Precision Medicine Gap

August 20, 2020 8:00 AM EDT | Source: Reportable, Inc.

San Francisco, California--(Newsfile Corp. - August 20, 2020) - Cofactor Genomics, the company bridging the precision medicine gap, announced today that the United States Patent and Trademark Office (USPTO) has granted Patent No. 10636512 protecting the Company's predictive immune modeling technology. The patent covers translation of RNA present in tumors into immune composition and its use in predicting response to immunotherapy in cancer patients.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways

  • Cofactor Genomics granted U.S. patent for predictive immune modeling technology

  • Patent covers translation of RNA present in tumors into immune composition and its use in predicting response to immunotherapy in cancer patients

  • Provides Cofactor freedom-to-operate in multidimensional biomarker diagnostic space

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7294/62111_e3a5baa944873981_001.jpg

Select image to view the full announcement, including downloadable images, bios, and more

Cofactor Genomics

Cofactor Genomics is bridging the precision medicine gap by building diagnostic tools to match the right patient to the right treatment at the right time. Predicting patient response to therapy currently relies on isolated, single-analyte biomarkers that have failed to deliver accurate therapy response predictions, resulting in unnecessary healthcare costs, and most harmfully, negative outcomes for patients. Cofactor's products use Predictive Immune Modeling, which leverages RNA data and machine learning to combine biological signals, creating multidimensional biomarkers to deliver on the promise of precision medicine. Cofactor Genomics offers its full-service molecular, informatic, and database tools to make drug discovery, clinical trials and therapy selection more successful.and others.

Media Contact:
Mariesa Kemble, Chronic Communications Inc.
kemblem@aol.com
(608) 850-4745

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/62111

info